Brokers Set Expectations for MediWound Ltd.’s Q3 2024 Earnings (NASDAQ:MDWD)

MediWound Ltd. (NASDAQ:MDWD) – Analysts at HC Wainwright raised their Q3 2024 earnings estimates for MediWound in a research report issued on Thursday, August 15th. HC Wainwright analyst S. Ramakanth now expects that the biopharmaceutical company will post earnings per share of ($0.49) for the quarter, up from their prior forecast of ($0.55). HC Wainwright currently has a “Buy” rating and a $28.00 target price on the stock. The consensus estimate for MediWound’s current full-year earnings is ($1.86) per share. HC Wainwright also issued estimates for MediWound’s Q4 2024 earnings at ($0.62) EPS, FY2024 earnings at ($2.14) EPS, Q1 2025 earnings at ($0.62) EPS, Q2 2025 earnings at ($0.62) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.55) EPS, FY2025 earnings at ($2.26) EPS, FY2026 earnings at ($1.00) EPS and FY2028 earnings at $2.94 EPS.

Several other brokerages also recently commented on MDWD. Maxim Group boosted their target price on MediWound from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, July 16th. StockNews.com upgraded MediWound to a “sell” rating in a report on Monday, August 5th.

MediWound Trading Up 6.1 %

Shares of MediWound stock opened at $19.27 on Monday. The stock has a market capitalization of $178.90 million, a price-to-earnings ratio of -13.96 and a beta of 0.81. The firm’s 50-day moving average price is $17.45 and its two-hundred day moving average price is $16.32. MediWound has a 1-year low of $7.10 and a 1-year high of $24.00.

MediWound (NASDAQ:MDWD) last issued its earnings results on Wednesday, May 29th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.01. MediWound had a negative net margin of 64.24% and a negative return on equity of 21.67%. The business had revenue of $4.96 million for the quarter, compared to analyst estimates of $4.65 million.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Rhumbline Advisers acquired a new position in shares of MediWound during the second quarter valued at $131,000. Bank of New York Mellon Corp acquired a new position in MediWound during the 2nd quarter valued at about $342,000. Rosalind Advisors Inc. boosted its stake in shares of MediWound by 5.7% in the 2nd quarter. Rosalind Advisors Inc. now owns 513,490 shares of the biopharmaceutical company’s stock valued at $7,969,000 after purchasing an additional 27,500 shares during the last quarter. Essex Investment Management Co. LLC grew its position in shares of MediWound by 241.6% during the 1st quarter. Essex Investment Management Co. LLC now owns 132,487 shares of the biopharmaceutical company’s stock worth $1,888,000 after buying an additional 93,705 shares during the period. Finally, Janney Montgomery Scott LLC bought a new stake in shares of MediWound during the first quarter worth approximately $427,000. 46.83% of the stock is currently owned by institutional investors.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.